Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Pediatr ; 217: 172-176.e1, 2020 02.
Article in English | MEDLINE | ID: mdl-31761430

ABSTRACT

OBJECTIVE: To evaluate adherence to annual transcranial Doppler ultrasound (TCD) screening to prevent stroke among patients with sickle cell anemia (SCA) seen in the emergency department (ED). STUDY DESIGN: This retrospective chart review included patients with SCA seen at a large pediatric ED over 64 weeks. Patients who did not need a TCD (age <2 or ≥16 years, on chronic transfusions, history of an inadequate TCD) or were not followed at the study institution were excluded. Patients who had received a TCD in the last 12 months (TCD adherent) were compared with patients who had not (TCD nonadherent). RESULTS: During the study period, 257 patients with SCA in need of an annual TCD were identified and 63 patients (25%) had not received an annual TCD, including 19 patients (7%) who had never had a TCD. All TCD adherent patients had a clinic visit in the last year compared with 75% of TCD nonadherent patients, P < .0001. The mean interval time since the last hematology clinic appointment from the ED encounter was greater for the TCD nonadherent group: 70 vs 270 days, P < .0001. Demographics including markers of socioeconomic status were not significantly different between the 2 groups. CONCLUSIONS: Patients with SCA who present to the ED and are nonadherent to TCD screening guidelines are less likely to have had a recent hematology clinic visit. Future interventions to improve screening for stroke in SCA should target this patient population seen in the ED but not clinic.


Subject(s)
Anemia, Sickle Cell/complications , Cerebrovascular Circulation/physiology , Emergency Service, Hospital , Mass Screening/methods , Patient Compliance , Stroke/diagnosis , Ultrasonography, Doppler, Transcranial/methods , Adolescent , Anemia, Sickle Cell/diagnosis , Child , Child, Preschool , District of Columbia/epidemiology , Female , Follow-Up Studies , Humans , Incidence , Male , Retrospective Studies , Stroke/epidemiology , Stroke/etiology
2.
J Pediatr ; 198: 53-59, 2018 07.
Article in English | MEDLINE | ID: mdl-29628414

ABSTRACT

OBJECTIVE: To describe the incidence and characteristics of central venous catheter (CVC)-related thrombosis in hospitalized pediatric patients with active inflammatory bowel disease (IBD) and report the potential usefulness of anticoagulant thromboprophylaxis (AT). STUDY DESIGN: We conducted a retrospective study of patients who were admitted to our children's hospital in the last 2 years with active IBD and required a CVC and identified all patients with an objectively confirmed symptomatic CVC-related thrombosis. To assess the usefulness of a recently implemented institutional AT protocol, we compared the frequency of CVC-related thrombosis, nadir hemoglobin, and red blood cell transfusion requirements in patients who received AT with those who did not during the study period. RESULTS: A total of 40 patients with IBD who required 47 consecutive hospitalizations were included. AT was administered during 24 of 47 hospitalizations (51%). Patients who received AT were similar to those who did not receive AT with regard to demographics, IBD phenotypes, extent of colonic involvement, and thrombotic risk factors. CVC-related thrombosis occurred in 5 of 23 hospitalizations (22%) in which AT was withheld compared with 0 of 24 hospitalizations (0%) in which patients received AT (P = .02). The red blood cell transfusion requirements and nadir hemoglobin were not significantly different between the 2 groups. CONCLUSIONS: We observed a high incidence of CVC-related thrombosis in hospitalized children with IBD. Administration of AT in our population was associated with significant reduction in CVC-related thrombosis without evidence of increased bleeding.


Subject(s)
Anticoagulants/therapeutic use , Catheterization, Central Venous/adverse effects , Central Venous Catheters/adverse effects , Enoxaparin/therapeutic use , Inflammatory Bowel Diseases/therapy , Venous Thrombosis/epidemiology , Adolescent , Child , Female , Hospitalization , Humans , Incidence , Male , Retrospective Studies , Venous Thrombosis/prevention & control
3.
Pediatr Ann ; 44(7): e181-7, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26171708

ABSTRACT

Severe combined immunodeficiency disorders (SCID) are a group of primary immunodeficiencies resulting from any one of a diverse group of mutations impacting T-cell development. SCID is diagnosed and classified through assessment of the lymphocyte subset(s) affected and by the mechanisms responsible for the primary immune defect. Regardless of the genetics involved, patients invariably succumb to an early death without medical intervention. In the past, patients were primarily identified either by previous family history, physical manifestations, or after the onset of symptoms. However, the introduction of newborn screening for SCID has allowed the pediatrician to identify these patients at a much earlier age, greatly improving their survival. Currently, 23 states include SCID testing for T-cell deficiencies in their newborn screening platform. Protocols for confirmatory testing and medical intervention after a positive screen vary slightly from state-to-state. However, the standard curative treatment remains stem cell transplantation, although depending on the genetic cause of the disease, enzyme replacement and gene therapy may also be considered.


Subject(s)
Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/genetics , T-Lymphocytes/pathology , Enzyme Replacement Therapy , Female , Genetic Therapy , Hematopoietic Stem Cell Transplantation , Humans , Infant, Newborn , Mass Screening , Mutation , Severe Combined Immunodeficiency/prevention & control , Severe Combined Immunodeficiency/therapy
4.
Proteins ; 82(10): 2552-64, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24895213

ABSTRACT

Betaine-homocysteine S-methyltransferase (BHMT) is a zinc-dependent methyltransferase that uses betaine as the methyl donor for the remethylation of homocysteine to form methionine. This reaction supports S-adenosylmethionine biosynthesis, which is required for hundreds of methylation reactions in humans. Herein we report that BHMT is activated by potassium ions with an apparent K(M) for K⁺ of about 100 µM. The presence of potassium ions lowers the apparent K(M) of the enzyme for homocysteine, but it does not affect the apparent K(M) for betaine or the apparent k(cat) for either substrate. We employed molecular dynamics (MD) simulations to theoretically predict and protein crystallography to experimentally localize the binding site(s) for potassium ion(s). Simulations predicted that K⁺ ion would interact with residues Asp26 and/or Glu159. Our crystal structure of BHMT bound to homocysteine confirms these sites of interaction and reveals further contacts between K⁺ ion and BHMT residues Gly27, Gln72, Gln247, and Gly298. The potassium binding residues in BHMT partially overlap with the previously identified DGG (Asp26-Gly27-Gly28) fingerprint in the Pfam 02574 group of methyltransferases. Subsequent biochemical characterization of several site-specific BHMT mutants confirmed the results obtained by the MD simulations and crystallographic data. Together, the data herein indicate that the role of potassium ions in BHMT is structural and that potassium ion facilitates the specific binding of homocysteine to the active site of the enzyme.


Subject(s)
Betaine-Homocysteine S-Methyltransferase/metabolism , Homocysteine/metabolism , Models, Molecular , Potassium/metabolism , Betaine/chemistry , Betaine/metabolism , Betaine-Homocysteine S-Methyltransferase/chemistry , Betaine-Homocysteine S-Methyltransferase/genetics , Binding Sites , Catalytic Domain , Crystallography, X-Ray , Databases, Protein , Enzyme Activation , Homocysteine/chemistry , Humans , Kinetics , Molecular Dynamics Simulation , Mutagenesis, Site-Directed , Mutant Proteins/chemistry , Mutant Proteins/metabolism , Potassium/chemistry , Protein Conformation , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...